Kodiak Sciences Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 100.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.30B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Details
| Name | Kodiak Sciences Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 141 |
| Founded | 2009 |
| Ipo Date | 2018-10-04 |
| Ceo | Victor Perlroth |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US50015M1099 |
| Cusip | 50015M109 |
| Cik | 0001468748 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| John A. Borgeson CPA, M.B.A. | Executive Vice President, Chief Financial Officer and Secretary |
| Wayne To M.Phil. | Chief Technology Officer |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer |
| Dr. Hong Liang Ph.D. | Senior Vice President of Development |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development and Manufacturing |
| Almas Qudrat M.Sc. | Chief Quality Officer |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer |
| Dr. Laurent Ducay Ph.D. | Senior Vice President of Biologics Development and Manufacturing |
Contact
| Address | 1250 Page Mill Road, Palo Alto, California 94304, United States |
| Phone | 650 281 0850 |
| Website | https://kodiak.com |